These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
529 related articles for article (PubMed ID: 11157196)
21. HAMI 3379, a CysLT2R antagonist, dose- and time-dependently attenuates brain injury and inhibits microglial inflammation after focal cerebral ischemia in rats. Shi QJ; Wang H; Liu ZX; Fang SH; Song XM; Lu YB; Zhang WP; Sa XY; Ying HZ; Wei EQ Neuroscience; 2015 Apr; 291():53-69. PubMed ID: 25681271 [TBL] [Abstract][Full Text] [Related]
22. Neuroprotective effect of STAZN, a novel azulenyl nitrone antioxidant, in focal cerebral ischemia in rats: dose-response and therapeutic window. Ley JJ; Belayev L; Saul I; Becker DA; Ginsberg MD Brain Res; 2007 Nov; 1180():101-10. PubMed ID: 17945201 [TBL] [Abstract][Full Text] [Related]
23. Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. Liu XF; Fawcett JR; Thorne RG; DeFor TA; Frey WH J Neurol Sci; 2001 Jun; 187(1-2):91-7. PubMed ID: 11440750 [TBL] [Abstract][Full Text] [Related]
24. Usefulness of postischemic thrombolysis with or without neuroprotection in a focal embolic model of cerebral ischemia. Yang Y; Li Q; Miyashita H; Howlett W; Siddiqui M; Shuaib A J Neurosurg; 2000 May; 92(5):841-7. PubMed ID: 10794299 [TBL] [Abstract][Full Text] [Related]
25. Continuous oral administration of atorvastatin ameliorates brain damage after transient focal ischemia in rats. Saito T; Nito C; Ueda M; Inaba T; Kamiya F; Muraga K; Katsura K; Katayama Y Life Sci; 2014 Jan; 94(2):106-14. PubMed ID: 24333133 [TBL] [Abstract][Full Text] [Related]
26. SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection. Legos JJ; Lenhard SC; Haimbach RE; Schaeffer TR; Bentley RG; McVey MJ; Chandra S; Irving EA; Andrew A Parsons ; Barone FC Exp Neurol; 2008 Jul; 212(1):53-62. PubMed ID: 18462720 [TBL] [Abstract][Full Text] [Related]
27. Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion. Gamboa J; Blankenship DA; Niemi JP; Landreth GE; Karl M; Hilow E; Sundararajan S Neuroscience; 2010 Oct; 170(3):846-57. PubMed ID: 20691766 [TBL] [Abstract][Full Text] [Related]
28. LAU-0901, a novel platelet-activating factor antagonist, is highly neuroprotective in cerebral ischemia. Belayev L; Khoutorova L; Atkins K; Gordon WC; Alvarez-Builla J; Bazan NG Exp Neurol; 2008 Dec; 214(2):253-8. PubMed ID: 18793637 [TBL] [Abstract][Full Text] [Related]
29. The low molecular weight heparin enoxaparin reduces infarct size in a rat model of temporary focal ischemia. Quartermain D; Li YS; Jonas S Cerebrovasc Dis; 2003; 16(4):346-55. PubMed ID: 13130175 [TBL] [Abstract][Full Text] [Related]
30. Enoxaparin in experimental stroke: neuroprotection and therapeutic window of opportunity. Mary V; Wahl F; Uzan A; Stutzmann JM Stroke; 2001 Apr; 32(4):993-9. PubMed ID: 11283402 [TBL] [Abstract][Full Text] [Related]
32. Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model. Shuaib A; Xu Wang C; Yang T; Noor R Stroke; 2002 Dec; 33(12):3033-7. PubMed ID: 12468809 [TBL] [Abstract][Full Text] [Related]
33. Bryostatin improves survival and reduces ischemic brain injury in aged rats after acute ischemic stroke. Tan Z; Turner RC; Leon RL; Li X; Hongpaisan J; Zheng W; Logsdon AF; Naser ZJ; Alkon DL; Rosen CL; Huber JD Stroke; 2013 Dec; 44(12):3490-7. PubMed ID: 24172582 [TBL] [Abstract][Full Text] [Related]
34. A glycine site antagonist, ZD9379, reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion. Tatlisumak T; Takano K; Meiler MR; Fisher M Stroke; 1998 Jan; 29(1):190-5. PubMed ID: 9445350 [TBL] [Abstract][Full Text] [Related]
35. Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Wang Y; Zhang ZG; Rhodes K; Renzi M; Zhang RL; Kapke A; Lu M; Pool C; Heavner G; Chopp M Br J Pharmacol; 2007 Aug; 151(8):1377-84. PubMed ID: 17603558 [TBL] [Abstract][Full Text] [Related]
36. Early Treatment with Poly(ADP-Ribose) Polymerase-1 Inhibitor (JPI-289) Reduces Infarct Volume and Improves Long-Term Behavior in an Animal Model of Ischemic Stroke. Kim Y; Kim YS; Kim HY; Noh MY; Kim JY; Lee YJ; Kim J; Park J; Kim SH Mol Neurobiol; 2018 Sep; 55(9):7153-7163. PubMed ID: 29383691 [TBL] [Abstract][Full Text] [Related]
37. In vivo neuroprotective effects of ACEA 1021 confirmed by magnetic resonance imaging in ischemic stroke. Petty MA; Neumann-Haefelin C; Kalisch J; Sarhan S; Wettstein JG; Juretschke HP Eur J Pharmacol; 2003 Aug; 474(1):53-62. PubMed ID: 12909195 [TBL] [Abstract][Full Text] [Related]
38. Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. Belayev L; Marcheselli VL; Khoutorova L; Rodriguez de Turco EB; Busto R; Ginsberg MD; Bazan NG Stroke; 2005 Jan; 36(1):118-23. PubMed ID: 15569878 [TBL] [Abstract][Full Text] [Related]
39. Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. Schäbitz WR; Sommer C; Zoder W; Kiessling M; Schwaninger M; Schwab S Stroke; 2000 Sep; 31(9):2212-7. PubMed ID: 10978054 [TBL] [Abstract][Full Text] [Related]
40. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--I: Physiological responses and safety results. Ginsberg MD; Hill MD; Palesch YY; Ryckborst KJ; Tamariz D Stroke; 2006 Aug; 37(8):2100-6. PubMed ID: 16809571 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]